We showed that melanoma patients who were responsive to anti-PD-1 expressed significantly higher levels of TAP1, TAPASIN, LMP2, but not TAP2, compared to those who were not responsive to this therapy (Figure 4A). Here, PDCD1 is linked to melanoma.